Detection of miR-1246, miR-23a and miR-451 in sera of colorectal carcinoma patients: a case-control study in Cairo University hospital.
miR-1246
miR-23a
miR-451
Journal
African health sciences
ISSN: 1729-0503
Titre abrégé: Afr Health Sci
Pays: Uganda
ID NLM: 101149451
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
1
7
2021
Statut:
ppublish
Résumé
Colorectal cancer (CRC) has high morbidity and mortality rates. Invasive techniques and other laboratory tests with variable sensitivity and specificity are currently used in diagnosis. Micro ribonucleic acids (miRNAs) have bio vital roles in cell proliferation and apoptosis. Dys-regulation of miRNAs is linked to tumour genesis. The objective of this study was to evaluate the specificity and sensitivity of serum non-invasive biomarkers (micro-RNAs), miR-1246, miR-23a, and miR-451in CRC patients. Peripheral expression of three miRNAs (miR-1246, miR-23a and miR-451) was investigated in sera of 37 CRC Egyptian patients and 30 healthy controls, using quantitative real-time polymerase chain reaction trying to reach the optimal non-invasive combination of miRNAs. Serum miR-1246 was up-regulated in sera of CRC patients compared to normal controls (fold change = 3.55; P<0.001) and showed 100% sensitivity and 80% specificity in diagnosis of CRC. Serum miR-451 was significantly down-regulated in CRC patients (fold change = -4.86; p= 0.014), whereas, miR-23a was down-regulated but this was not statistically significant. Up-regulation of miR-1246 and down-regulation of miR-451 in the sera of primary CRC Egyptian patients were confirmed with high sensitivity and specificity. Large-scale studies on a wider spectrum of miRNAs in Egyptian CRC patients are needed.
Sections du résumé
BACKGROUND
BACKGROUND
Colorectal cancer (CRC) has high morbidity and mortality rates. Invasive techniques and other laboratory tests with variable sensitivity and specificity are currently used in diagnosis. Micro ribonucleic acids (miRNAs) have bio vital roles in cell proliferation and apoptosis. Dys-regulation of miRNAs is linked to tumour genesis. The objective of this study was to evaluate the specificity and sensitivity of serum non-invasive biomarkers (micro-RNAs), miR-1246, miR-23a, and miR-451in CRC patients.
METHODS
METHODS
Peripheral expression of three miRNAs (miR-1246, miR-23a and miR-451) was investigated in sera of 37 CRC Egyptian patients and 30 healthy controls, using quantitative real-time polymerase chain reaction trying to reach the optimal non-invasive combination of miRNAs.
RESULTS
RESULTS
Serum miR-1246 was up-regulated in sera of CRC patients compared to normal controls (fold change = 3.55; P<0.001) and showed 100% sensitivity and 80% specificity in diagnosis of CRC. Serum miR-451 was significantly down-regulated in CRC patients (fold change = -4.86; p= 0.014), whereas, miR-23a was down-regulated but this was not statistically significant.
CONCLUSION
CONCLUSIONS
Up-regulation of miR-1246 and down-regulation of miR-451 in the sera of primary CRC Egyptian patients were confirmed with high sensitivity and specificity. Large-scale studies on a wider spectrum of miRNAs in Egyptian CRC patients are needed.
Identifiants
pubmed: 33402976
doi: 10.4314/ahs.v20i3.33
pii: jAFHS.v20.i3.pg1283
pmc: PMC7751536
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN1246 microRNA, human
0
MIRN23a microRNA, human
0
MIRN451 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1283-1291Informations de copyright
© 2020 Salah M et al.
Références
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
pubmed: 21685461
PLoS One. 2016 May 02;11(5):e0154130
pubmed: 27135244
Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1766-74
pubmed: 20551304
World J Surg Oncol. 2013 Apr 18;11:88
pubmed: 23597032
EMBO Rep. 2011 Jun 03;12(8):811-7
pubmed: 21637297
Glob Health Action. 2013 Feb 05;6:20100
pubmed: 23394856
J Gastrointest Oncol. 2012 Jun;3(2):105-19
pubmed: 22811878
Eur J Cancer. 2007 Jun;43(9):1348-60
pubmed: 17512720
Oncotarget. 2016 Apr 12;7(15):19824-39
pubmed: 26918346
Int J Surg. 2014;12(9):893-6
pubmed: 25026311
Oncol Rep. 2015 Mar;33(3):1335-41
pubmed: 25591821
PLoS One. 2013 May 14;8(5):e62880
pubmed: 23690963
Asian Pac J Cancer Prev. 2013;14(8):4699-704
pubmed: 24083729
Stem Cells. 2011 Nov;29(11):1661-71
pubmed: 21948564
Oncology. 2006;70(4):255-64
pubmed: 16899980
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2014-24
pubmed: 16609010
Oncotarget. 2017 Mar 7;8(10):17328-17346
pubmed: 28061475
PLoS One. 2014 Apr 17;9(4):e94060
pubmed: 24743265
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Cancer Discov. 2012 Jun;2(6):540-53
pubmed: 22628407
Gastroenterol Res Pract. 2013;2013:457901
pubmed: 23737765
J Clin Gastroenterol. 2011 Apr;45(4):355-60
pubmed: 21278583
PLoS One. 2014 Apr 04;9(4):e92921
pubmed: 24705249
J Med Biochem. 2019 Mar 03;38(2):109-117
pubmed: 30867638
World J Gastroenterol. 2012 Aug 14;18(30):3997-4003
pubmed: 22912550
Clin Cancer Res. 2009 Apr 1;15(7):2281-90
pubmed: 19318487
BMC Cancer. 2013 Jun 08;13:280
pubmed: 23758639
Cancer Genomics Proteomics. 2012 Jul-Aug;9(4):179-92
pubmed: 22798503
Int J Mol Sci. 2018 Sep 27;19(10):
pubmed: 30262723
Methods Mol Biol. 2011;676:211-23
pubmed: 20931400
Biochim Biophys Acta. 2014 Nov;1839(11):1256-72
pubmed: 25218966
Asian Pac J Cancer Prev. 2015;16(12):4853-8
pubmed: 26163603
World J Gastroenterol. 2014 May 28;20(20):6055-72
pubmed: 24876728
Exp Mol Pathol. 2018 Dec;105(3):260-271
pubmed: 30213464